IONS

IONIS PHARMACEUTICALS INC

Pharmaceutical Preparations · SIC 2834CIK 874015Held by 9 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$944.0M

Net Income FY2025

$(381.0M)

EPS (Basic, as reported)

$-2.38

Net Margin FY2025

-40.4%

ROE FY2025

-78.0%

Total Equity

$489.0M

Shares Out

166M

Business description

IONIS PHARMACEUTICALS INC — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2008–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 373 → 944 +10.9% CAGR

Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue3735146001,123729810587788705944

Cost of revenue00(2)(4)(12)(11)(14)(9)(11)(16)

Research & development(340)(372)(412)(461)(531)(638)—(900)(902)(916)

Selling, general & administrative(49)(108)(245)(287)(354)(186)(150)(233)(267)(394)

General & administrative(49)—————————

Total operating expenses(393)(483)(661)(757)(901)(841)(998)(1,141)(1,180)(1,325)

Operating income(46)25(61)366(172)(30)(410)(354)(475)(382)

Interest expense(39)(45)(45)(49)(45)(9)(8)(13)(17)(17)

Other income (expense), net0(4)0(1)0(1)(7)141(15)

Pre-tax income(84)(23)(76)339(135)(29)(258)(334)(460)(380)

Income tax expense(3)(6)(291)(44)(317)(1)(12)(32)(6)(2)

Net income(87)(6)274294(451)(29)(270)(366)(454)(381)

EPS — basic($0.72)$0.08$2.09$2.12($3.23)($0.20)($1.90)($2.56)($3.04)($2.38)

EPS — diluted($0.72)$0.08$2.07$2.08($3.23)($0.20)($1.90)($2.56)($3.04)($2.38)

Shares outstanding — basic (M)121124132140140141142143150160

Shares outstanding — diluted (M)121126134143140141142143150160

Showing the latest 10 of 18 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.